Want to see KR:271980 full AI Analyst Report?
Jeil Pharmaceutical Co. Ltd. (271980) Ratios
Jeil Pharmaceutical Co. Ltd. Ratios
KR:271980's free cash flow for Q2 2026 was $-14.66B. For the 2026 fiscal year, KR:271980's free cash flow was decreased by $-6.25B and operating cash flow was $-8.41B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.29 | 1.18 | 1.00 | 1.09 | 1.28 |
| Quick Ratio | 0.85 | 0.82 | 0.65 | 0.72 | 0.82 |
| Cash Ratio | 0.20 | 0.18 | 0.10 | 0.12 | 0.12 |
| Solvency Ratio | 0.14 | -0.06 | 0.04 | -0.01 | -0.01 |
| Operating Cash Flow Ratio | -0.02 | 0.01 | -0.02 | -0.06 | 0.09 |
| Short-Term Operating Cash Flow Coverage | -0.06 | 0.05 | -0.08 | -0.35 | 0.63 |
| Net Current Asset Value | $ 52.07B | $ 36.65B | $ -13.25B | $ -9.65B | $ 25.53B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.18 | 0.14 | 0.15 | 0.11 | 0.11 |
| Debt-to-Equity Ratio | 0.44 | 0.40 | 0.45 | 0.32 | 0.28 |
| Debt-to-Capital Ratio | 0.31 | 0.29 | 0.31 | 0.24 | 0.22 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.02 | 0.05 |
| Financial Leverage Ratio | 2.42 | 2.79 | 3.07 | 2.89 | 2.54 |
| Debt Service Coverage Ratio | 0.31 | -0.18 | 0.30 | -0.06 | -0.10 |
| Interest Coverage Ratio | 4.63 | -3.74 | 1.45 | -4.49 | -5.28 |
| Debt to Market Cap | 0.41 | 0.43 | 0.25 | 0.15 | 0.08 |
| Interest Debt Per Share | 6651.57 | 5541.59 | 5291.16 | 3661.05 | 3406.59 |
| Net Debt to EBITDA | 1.36 | -2.10 | 2.16 | -15.64 | -10.81 |
| Profitability Margins | |||||
| Gross Profit Margin | 36.79% | 25.19% | 25.37% | 21.71% | 22.26% |
| EBIT Margin | 3.59% | -3.11% | 1.09% | -1.40% | -1.59% |
| EBITDA Margin | 5.76% | -1.51% | 2.44% | -0.17% | -0.29% |
| Operating Profit Margin | 3.59% | -2.69% | 1.20% | -1.87% | -1.48% |
| Pretax Profit Margin | 6.17% | -3.91% | 0.26% | -1.83% | -1.97% |
| Net Profit Margin | 4.13% | -4.25% | 0.69% | -1.81% | -1.78% |
| Continuous Operations Profit Margin | 5.65% | -4.36% | 0.72% | -2.08% | -2.14% |
| Net Income Per EBT | 66.91% | 108.79% | 261.20% | 98.82% | 90.16% |
| EBT Per EBIT | 171.93% | 145.53% | 21.94% | 98.09% | 133.13% |
| Return on Assets (ROA) | 4.58% | -5.70% | 1.03% | -2.87% | -2.92% |
| Return on Equity (ROE) | 11.08% | -15.93% | 3.16% | -8.29% | -7.42% |
| Return on Capital Employed (ROCE) | 7.58% | -8.09% | 5.16% | -7.17% | -5.08% |
| Return on Invested Capital (ROIC) | 5.16% | -6.17% | 3.70% | -5.79% | -4.39% |
| Return on Tangible Assets | 4.72% | -5.85% | 1.04% | -2.93% | -2.95% |
| Earnings Yield | 10.50% | -18.04% | 1.94% | -4.28% | -2.52% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.01 | 4.05 | 4.81 | 4.58 | 4.61 |
| Payables Turnover | 4.03 | 3.92 | 3.76 | 3.73 | 3.56 |
| Inventory Turnover | 3.43 | 5.05 | 4.94 | 5.70 | 5.32 |
| Fixed Asset Turnover | 3.83 | 4.82 | 5.30 | 5.22 | 5.57 |
| Asset Turnover | 1.11 | 1.34 | 1.49 | 1.58 | 1.64 |
| Working Capital Turnover Ratio | 9.40 | 28.06 | 66.46 | 16.85 | 11.47 |
| Cash Conversion Cycle | 106.81 | 69.23 | 52.58 | 45.86 | 45.21 |
| Days of Sales Outstanding | 91.09 | 90.10 | 75.85 | 79.75 | 79.13 |
| Days of Inventory Outstanding | 106.26 | 72.32 | 73.90 | 64.00 | 68.65 |
| Days of Payables Outstanding | 90.54 | 93.19 | 97.18 | 97.89 | 102.58 |
| Operating Cycle | 197.35 | 162.42 | 149.75 | 143.75 | 147.78 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -386.92 | 220.49 | -341.35 | -1039.24 | 1307.43 |
| Free Cash Flow Per Share | -933.15 | -233.31 | -997.64 | -2202.76 | 938.30 |
| Dividend Paid and CapEx Coverage Ratio | -0.71 | 0.44 | -0.48 | -0.85 | 2.98 |
| Capital Expenditure Coverage Ratio | -0.71 | 0.49 | -0.52 | -0.89 | 3.54 |
| Operating Cash Flow Coverage Ratio | -0.06 | 0.04 | -0.07 | -0.30 | 0.40 |
| Operating Cash Flow to Sales Ratio | -0.01 | 0.00 | -0.01 | -0.02 | 0.03 |
| Free Cash Flow Yield | -6.16% | -2.05% | -5.63% | -10.49% | 2.77% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 9.44 | -5.54 | 51.66 | -23.38 | -39.65 |
| Price-to-Sales (P/S) Ratio | 0.39 | 0.24 | 0.36 | 0.42 | 0.71 |
| Price-to-Book (P/B) Ratio | 1.06 | 0.88 | 1.63 | 1.94 | 2.94 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -16.24 | -48.86 | -17.76 | -9.53 | 36.08 |
| Price-to-Operating Cash Flow Ratio | -39.16 | 51.70 | -51.91 | -20.21 | 25.89 |
| Price-to-Earnings Growth (PEG) Ratio | -0.05 | 0.01 | -0.37 | -4.50 | 0.14 |
| Enterprise Value Multiple | 8.19 | -17.76 | 16.75 | -268.82 | -255.70 |
| Enterprise Value | 267.32B | 188.34B | 296.73B | 324.98B | 516.35B |
| EV to EBITDA | 8.19 | -17.76 | 16.75 | -268.82 | -255.70 |
| EV to Sales | 0.47 | 0.27 | 0.41 | 0.45 | 0.74 |
| EV to Free Cash Flow | -19.48 | -55.40 | -20.38 | -10.12 | 37.67 |
| EV to Operating Cash Flow | -46.98 | 58.62 | -59.58 | -21.46 | 27.03 |
| Tangible Book Value Per Share | 16020.98 | 14132.92 | 10466.17 | 10031.94 | 11197.54 |
| Shareholders’ Equity Per Share | 14353.71 | 12911.74 | 10867.67 | 10834.24 | 11514.37 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.08 | -0.12 | -1.71 | -0.13 | -0.08 |
| Revenue Per Share | 38513.41 | 48349.03 | 49783.69 | 49552.65 | 47963.12 |
| Net Income Per Share | 1590.21 | -2056.54 | 343.00 | -898.17 | -853.81 |
| Tax Burden | 0.67 | 1.09 | 2.61 | 0.99 | 0.90 |
| Interest Burden | 1.72 | 1.26 | 0.24 | 1.31 | 1.24 |
| Research & Development to Revenue | 0.08 | 0.06 | 0.06 | 0.06 | 0.06 |
| SG&A to Revenue | 0.16 | 0.12 | 0.11 | 0.10 | 0.11 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -0.24 | -0.11 | -0.96 | 1.01 | -1.27 |
Currency in KRW